Innovative Food Holdings Announces Second Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Innovative Food Holdings Announces Second Quarter 2016 Financial Results

BONITA SPRINGS, FL--(Marketwired - Aug 15, 2016) -  Innovative Food Holdings, Inc. ( OTCQB : IVFH ) today reported financial results for the second quarter and six months ended June 30, 2016.

Financial Highlights:

  • Revenue for the second quarter of $8.3 million, an increase of approximately 9% compared to $7.6 million in Q2 2015
  • Six month 2016 revenue increased 15% to $16.3 million as compared to $14.2 million for the same period in 2015
  • GAAP Net Income increased over 300% to $575,000 compared to $135,000 in Q2 2015
  • Fully Diluted GAAP EPS increased by 300% to $0.02 per share compared to $0.005 in Q2 2015
  • Cash EBITDA (EBITDA excluding stock related expenses) increased by over 10% to $1.03 million vs $923,000 in Q2 2015

Sam Klepfish, CEO of Innovative Food Holdings, commented, "We are pleased that we were able to drive record top and bottom line results. As we enter the second half of 2016 we will continue to focus on driving sustainable sales and profitability growth, and towards increasing inherent value for IVFH shareholders."

Three Months Ended

Revenue for the second quarter of 2016 was $8.3 million, up approximately 9% as compared to $7.6 million in the second quarter of 2015. Adjusted net income (net income excluding amortization and stock related expenses) increased to $968,000 vs $893,000 in Q2 of 2015. Adjusted fully diluted EPS (see table) increased to $0.03 compared to $0.027 in the second quarter of 2015. Cash EBITDA increased over 10% to $1.03 million compared to $923,000 in the second quarter of 2015. 

Six Months Ended

Revenue for the first six months of 2016 was $16.3 million, up approximately 15% as compared to $14.2 million for the first six months of 2015. Adjusted net income increased approximately 15% to $1.75 million vs $1.52 million in first six months of 2015. Adjusted fully diluted EPS increased to $0.055 compared to $0.049 for the first six months of 2015. Cash EBITDA increased over 20% to $1.89 million compared to $1.57 million in the first six months of 2015.

Conference call information:

The Conference call will take place on Monday, August 15, 2016 at 5:00 p.m. ET. The toll-free dial in number is 1-888-401-4669 and the international dial-in number is 1-719-457-2085 Conference ID: 3933215. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and will be available for replay until August 22, 2016 at http://public.viavid.com/index.php?id=120818

About Innovative Food Holdings Innovative Food Holdings' ( OTCQB : IVFH ) industry-leading specialty food platforms in the foodservice and consumer markets provide chefs and consumers direct access to the highest quality specialty food products across the United States.

In the direct-to-chef foodservice market, Innovative Food Holdings' automated direct-to-chef platform offers efficient, cost effective, and transparent direct sourcing and distribution of over 7,000 specialty food products delivered daily, to thousands of chefs nationwide.

Forward-Looking Statements

This release contains certain forward-looking statements and information relating to Innovative Food Holdings, Inc. (the "Company") that are based on the current beliefs of the Company's management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "should," "could," "anticipate," "believe," "intend," "plan," "might," "potentially" or "expect." The Company does not intend to update these forward-looking statements.

                 
         
    Three Month Ended June 30   Six Month Ended June 30
Continuing Operations   2016   2015   2016   2015
                 
Adjusted Operating Income and EPS                
Revenue     8,303,227     7,633,650     16,318,568     14,210,498  
Net Income (Loss)     575,263     135,703     955,909     (7,244 )
Amortization of Intangible Assets (1)     65,817     75,788     131,634     151,576  
Amortization of Discount on NP (2)     92,509     99,157     185,018     198,314  
Stock Related Expenses (3)     235,288     582,436     477,893     1,178,225  
Adjusted Net Income     968,877     893,084     1,750,454     1,520,871  
Weighted Average Pro Forma Fully Diluted Shares Outstanding (4)     31,883,014     32,850,968     31,839,607     31,293,252  
                           
Adjusted Fully Diluted EPS (4)   $ 0.030   $ 0.027   $ 0.055   $ 0.049  
         
    Three Month Ended June 30   Six Month Ended June 30
Cash EBITDA   2016   2015   2016   2015
Net Income (Loss)     575,263     135,703     955,909     (7,244 )
Interest     20,380     12,292     59,520     22,254  
Depreciation & Amortization     111,669     93,527     213,845     184,829  
Stock Related Expenses (3)     235,288     582,436     477,893     1,178,225  
Amortization of Discounts (2)     92,509     99,157     185,018     198,314  
                           
Cash EBITDA   $ 1,035,109   $ 923,115   $ 1,892,185   $ 1,576,378  
(1) Includes non cash amortization charges related to assets acquired
(2) Includes non cash amortization charges mainly associated with the GAAP recording of the discount on certain notes
(3) Includes stock and options based compensation and expenses
(4) Fully diluted adjusted GAAP EPS via treasury stock method without add-back to income for any expenses related to the converted or exercised securities
   

Management Contact Ronit Wallerstein Investor Relations Analyst (718) 645-1755 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading